Annual Operating Profit
$337.57 M
+$70.04 M+26.18%
31 December 2023
Summary:
Halozyme Therapeutics annual operaing income is currently $337.57 million, with the most recent change of +$70.04 million (+26.18%) on 31 December 2023. During the last 3 years, it has risen by +$193.32 million (+134.01%). HALO annual operating profit is now at all-time high.HALO Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
$163.20 M
+$45.96 M+39.21%
30 September 2024
Summary:
Halozyme Therapeutics quarterly operating income is currently $163.20 million, with the most recent change of +$45.96 million (+39.21%) on 30 September 2024. Over the past year, it has increased by +$74.92 million (+84.87%). HALO quarterly operating profit is now at all-time high.HALO Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
$477.01 M
+$74.92 M+18.63%
30 September 2024
Summary:
Halozyme Therapeutics TTM operating income is currently $477.01 million, with the most recent change of +$74.92 million (+18.63%) on 30 September 2024. Over the past year, it has increased by +$165.96 million (+53.36%). HALO TTM operating profit is now at all-time high.HALO TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +26.2% | +84.9% | +53.4% |
| 3 y3 years | +134.0% | +115.9% | +60.6% |
| 5 y5 years | +586.9% | +765.1% | +1439.2% |
HALO Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +134.0% | at high | +379.1% | at high | +97.2% |
| 5 y | 5 years | at high | +586.9% | at high | +609.0% | at high | +746.4% |
| alltime | all time | at high | +505.7% | at high | +609.0% | at high | +585.1% |
Halozyme Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $163.20 M(+39.2%) | $477.01 M(+18.6%) |
| June 2024 | - | $117.23 M(+22.7%) | $402.09 M(+6.0%) |
| Mar 2024 | - | $95.54 M(-5.4%) | $379.31 M(+12.4%) |
| Dec 2023 | $337.57 M(+26.2%) | $101.03 M(+14.4%) | $337.57 M(+8.5%) |
| Sept 2023 | - | $88.28 M(-6.5%) | $311.05 M(+1.6%) |
| June 2023 | - | $94.46 M(+75.6%) | $306.06 M(+24.6%) |
| Mar 2023 | - | $53.80 M(-27.8%) | $245.66 M(-8.2%) |
| Dec 2022 | $267.53 M(-3.0%) | $74.51 M(-10.5%) | $267.53 M(+7.2%) |
| Sept 2022 | - | $83.29 M(+144.5%) | $249.56 M(+3.2%) |
| June 2022 | - | $34.06 M(-55.0%) | $241.85 M(-19.6%) |
| Mar 2022 | - | $75.67 M(+33.8%) | $300.84 M(+9.0%) |
| Dec 2021 | $275.90 M(+91.3%) | $56.53 M(-25.2%) | $275.90 M(-7.1%) |
| Sept 2021 | - | $75.59 M(-18.8%) | $296.99 M(+13.5%) |
| June 2021 | - | $93.05 M(+83.4%) | $261.70 M(+32.0%) |
| Mar 2021 | - | $50.73 M(-34.6%) | $198.21 M(+37.4%) |
| Dec 2020 | $144.25 M(-313.4%) | $77.62 M(+92.6%) | $144.25 M(+317.3%) |
| Sept 2020 | - | $40.30 M(+36.4%) | $34.57 M(-214.2%) |
| June 2020 | - | $29.55 M(-1017.0%) | -$30.27 M(-59.0%) |
| Mar 2020 | - | -$3.22 M(-89.9%) | -$73.80 M(+9.2%) |
| Dec 2019 | -$67.61 M(-2.5%) | -$32.06 M(+30.7%) | -$67.61 M(+89.8%) |
| Sept 2019 | - | -$24.54 M(+75.6%) | -$35.62 M(-2.6%) |
| June 2019 | - | -$13.98 M(-571.2%) | -$36.56 M(-14.3%) |
| Mar 2019 | - | $2.97 M(-4277.5%) | -$42.65 M(-38.5%) |
| Dec 2018 | -$69.33 M(-185.6%) | -$71.00 K(-99.7%) | -$69.33 M(-222.3%) |
| Sept 2018 | - | -$25.47 M(+26.9%) | $56.67 M(-37.2%) |
| June 2018 | - | -$20.07 M(-15.3%) | $90.22 M(+6.4%) |
| Mar 2018 | - | -$23.71 M(-118.8%) | $84.82 M(+4.7%) |
| Dec 2017 | $81.00 M(-197.3%) | $125.93 M(+1459.1%) | $81.00 M(-220.0%) |
| Sept 2017 | - | $8.08 M(-131.7%) | -$67.50 M(-31.3%) |
| June 2017 | - | -$25.48 M(-7.4%) | -$98.32 M(+4.0%) |
| Mar 2017 | - | -$27.53 M(+21.9%) | -$94.57 M(+13.6%) |
| Dec 2016 | -$83.21 M(+203.1%) | -$22.57 M(-0.7%) | -$83.21 M(+50.8%) |
| Sept 2016 | - | -$22.74 M(+4.7%) | -$55.17 M(-0.9%) |
| June 2016 | - | -$21.72 M(+34.3%) | -$55.66 M(+87.4%) |
| Mar 2016 | - | -$16.17 M(-395.9%) | -$29.71 M(+8.2%) |
| Dec 2015 | -$27.45 M(-56.5%) | $5.46 M(-123.5%) | -$27.45 M(-25.3%) |
| Sept 2015 | - | -$23.24 M(-649.2%) | -$36.77 M(+12.9%) |
| June 2015 | - | $4.23 M(-130.4%) | -$32.56 M(-37.1%) |
| Mar 2015 | - | -$13.91 M(+261.2%) | -$51.73 M(-17.9%) |
| Dec 2014 | -$63.04 M(-21.6%) | -$3.85 M(-79.8%) | -$63.04 M(-21.7%) |
| Sept 2014 | - | -$19.03 M(+27.3%) | -$80.51 M(+0.7%) |
| June 2014 | - | -$14.94 M(-40.8%) | -$79.98 M(-8.2%) |
| Mar 2014 | - | -$25.22 M(+18.3%) | -$87.16 M(+8.4%) |
| Dec 2013 | -$80.43 M | -$21.32 M(+15.3%) | -$80.43 M(+26.6%) |
| Sept 2013 | - | -$18.49 M(-16.4%) | -$63.52 M(-2.4%) |
| June 2013 | - | -$22.12 M(+19.6%) | -$65.05 M(+14.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$18.50 M(+319.7%) | -$56.98 M(+6.3%) |
| Dec 2012 | -$53.63 M(+170.3%) | -$4.41 M(-78.0%) | -$53.63 M(-20.7%) |
| Sept 2012 | - | -$20.03 M(+42.6%) | -$67.65 M(+59.3%) |
| June 2012 | - | -$14.05 M(-7.2%) | -$42.46 M(+67.7%) |
| Mar 2012 | - | -$15.14 M(-17.8%) | -$25.32 M(+27.6%) |
| Dec 2011 | -$19.84 M(-63.4%) | -$18.43 M(-457.6%) | -$19.84 M(+2.8%) |
| Sept 2011 | - | $5.15 M(+66.4%) | -$19.29 M(-47.7%) |
| June 2011 | - | $3.10 M(-132.0%) | -$36.88 M(-29.3%) |
| Mar 2011 | - | -$9.66 M(-46.0%) | -$52.13 M(-3.9%) |
| Dec 2010 | -$54.26 M(-7.2%) | -$17.88 M(+43.8%) | -$54.26 M(+10.6%) |
| Sept 2010 | - | -$12.43 M(+2.3%) | -$49.05 M(-3.0%) |
| June 2010 | - | -$12.15 M(+3.1%) | -$50.56 M(-8.9%) |
| Mar 2010 | - | -$11.79 M(-7.0%) | -$55.49 M(-5.1%) |
| Dec 2009 | -$58.46 M(+15.9%) | -$12.68 M(-9.1%) | -$58.46 M(-6.9%) |
| Sept 2009 | - | -$13.94 M(-18.4%) | -$62.81 M(+4.6%) |
| June 2009 | - | -$17.08 M(+15.8%) | -$60.07 M(+10.5%) |
| Mar 2009 | - | -$14.76 M(-13.3%) | -$54.36 M(+7.8%) |
| Dec 2008 | -$50.43 M(+79.2%) | -$17.03 M(+52.0%) | -$50.43 M(+16.4%) |
| Sept 2008 | - | -$11.20 M(-1.5%) | -$43.34 M(+7.1%) |
| June 2008 | - | -$11.37 M(+5.0%) | -$40.45 M(+15.9%) |
| Mar 2008 | - | -$10.83 M(+9.1%) | -$34.90 M(+24.0%) |
| Dec 2007 | -$28.15 M(+80.6%) | -$9.93 M(+19.5%) | -$28.15 M(+23.0%) |
| Sept 2007 | - | -$8.31 M(+42.5%) | -$22.89 M(+24.4%) |
| June 2007 | - | -$5.83 M(+42.9%) | -$18.41 M(+15.1%) |
| Mar 2007 | - | -$4.08 M(-12.6%) | -$15.99 M(+2.6%) |
| Dec 2006 | -$15.58 M(+14.9%) | -$4.67 M(+22.0%) | -$15.58 M(+7.5%) |
| Sept 2006 | - | -$3.83 M(+12.0%) | -$14.49 M(+0.4%) |
| June 2006 | - | -$3.42 M(-7.0%) | -$14.43 M(+3.4%) |
| Mar 2006 | - | -$3.67 M(+2.6%) | -$13.96 M(+3.0%) |
| Dec 2005 | -$13.56 M(+49.2%) | -$3.58 M(-5.0%) | -$13.56 M(+8.4%) |
| Sept 2005 | - | -$3.77 M(+27.8%) | -$12.51 M(+4.2%) |
| June 2005 | - | -$2.95 M(-9.9%) | -$12.01 M(+7.7%) |
| Mar 2005 | - | -$3.27 M(+29.4%) | -$11.15 M(+22.7%) |
| Dec 2004 | -$9.09 M(<-9900.0%) | -$2.53 M(-22.5%) | -$9.09 M(+64.4%) |
| Sept 2004 | - | -$3.26 M(+56.2%) | -$5.53 M(+106.8%) |
| June 2004 | - | -$2.09 M(+73.0%) | -$2.67 M(+179.5%) |
| Mar 2004 | - | -$1.21 M(-217.0%) | -$956.20 K(<-9900.0%) |
| Dec 2003 | $0.00(0.0%) | $1.03 M(-352.9%) | $0.00(-100.0%) |
| Sept 2003 | - | -$408.20 K(+9.5%) | -$1.01 M(+64.0%) |
| June 2003 | - | -$372.90 K(+48.3%) | -$618.40 K(+134.4%) |
| Mar 2003 | - | -$251.40 K(-1458.9%) | -$263.80 K(<-9900.0%) |
| Dec 2002 | $0.00(-100.0%) | $18.50 K(-246.8%) | $0.00(-100.0%) |
| Sept 2002 | - | -$12.60 K(-31.1%) | -$18.50 K(+213.6%) |
| June 2002 | - | -$18.30 K(-247.6%) | -$5900.00(-147.6%) |
| Mar 2002 | - | $12.40 K | $12.40 K |
| Dec 2001 | -$39.70 K | - | - |
FAQ
- What is Halozyme Therapeutics annual operaing income?
- What is the all time high annual operating profit for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual operating profit year-on-year change?
- What is Halozyme Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly operating profit year-on-year change?
- What is Halozyme Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM operating profit year-on-year change?
What is Halozyme Therapeutics annual operaing income?
The current annual operating profit of HALO is $337.57 M
What is the all time high annual operating profit for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual operaing income is $337.57 M
What is Halozyme Therapeutics annual operating profit year-on-year change?
Over the past year, HALO annual operaing income has changed by +$70.04 M (+26.18%)
What is Halozyme Therapeutics quarterly operating income?
The current quarterly operating profit of HALO is $163.20 M
What is the all time high quarterly operating profit for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly operating income is $163.20 M
What is Halozyme Therapeutics quarterly operating profit year-on-year change?
Over the past year, HALO quarterly operating income has changed by +$74.92 M (+84.87%)
What is Halozyme Therapeutics TTM operating income?
The current TTM operating profit of HALO is $477.01 M
What is the all time high TTM operating profit for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM operating income is $477.01 M
What is Halozyme Therapeutics TTM operating profit year-on-year change?
Over the past year, HALO TTM operating income has changed by +$165.96 M (+53.36%)